While Applied Therapeutics has vowed to reapply or appeal the FDA’s recent rejection of its rare disease candidate govorestat ...

NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...

The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical ...

Applied Therapeutics has been sent a warning letter from the FDA over a clinical trial of its rare disease therapy govorestat ...

Shares of AT&T Inc. T rose sharply during Tuesday's session after the company updated its 2024 guidance, raising the bottom ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on APLT stock, giving a Buy rating on November 29.Don't Miss our ...

Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Applied Therapeutics regarding the New Drug Application (NDA) for govorestat for the treatment of classic ...

Fintel reports that on December 2, 2024, UBS downgraded their outlook for Applied Therapeutics (NasdaqGM:APLT) from Buy to ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

Dear Readers, the magical stage musical of the beloved “Mary Poppins”, currently playing at the 5th Avenue Theatre, may not ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s ...